GlobeNewswire·Oct 7, 2026, 8:00 AM ET

Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026

KYTX

Kyverna Therapeutics announced two abstracts selected for presentation at the MSToronto2026 meeting in Toronto, Canada, from October 21-23, 2026.
Full one-year results from the KYSA-8 registrational trial in stiff person syndrome (SPS) will demonstrate sustained clinical benefit & a well-tolerated safety profile with no high-grade CRS, ICANS, or IEC-HS cases.
Updated Phase 1 investigator-initiated trial data for progressive multiple sclerosis will continue to highlight encouraging clinical activity & a well-tolerated safety profile.
CEO Warner Biddle stated the company is advancing toward completing its Biologics License Application (BLA) for miv-cel in SPS this quarter & laying groundwork for a commercial launch.
If approved, miv-cel would become the first CAR T-cell therapy for an autoimmune disease & the first approved treatment for SPS.
A poster presentation on the 1-year analysis of KYSA-8 will be delivered by Dr. Amanda Piquet on October 21, 2026.
An oral presentation on safety & preliminary efficacy in progressive multiple sclerosis will be delivered by Dr. Jeff Dunn on October 23, 2026.
No FDA-approved treatments currently exist for SPS, which impacts an estimated 6,000 patients in the U.S. & often leads to permanent disability or mortality.
Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy designed to achieve deep B-cell depletion & durable drug-free remission with a single dose.
More than 100 patients have been treated with miv-cel across various autoimmune diseases to date, showing a consistent safety profile.
The company holds three FDA Regenerative Medicine Advanced Therapy (RMAT) designations for miv-cel in SPS, generalized myasthenia gravis, & non-active secondary progressive multiple sclerosis.